Heron Therapeutics Inc. (HTRX) Is Surging On Phase 3 Study Results
3/19/2018 9:40 AM ET
Heron Therapeutics Inc. (HRTX) announced Monday morning that its Phase 3 studies of HTX-011 in subjects undergoing bunionectomy and hernia repair achieved all primary and key secondary endpoints.
Heron Therapeutics gapped open sharply higher Monday and is now up 8.35 at $29.85 on above average volume. The stock has surged to a new high for the year.
Heron Therapeutics gapped open sharply higher Monday and is now up 8.35 at $29.85 on above average volume. The stock has surged to a new high for the year.
Aucun commentaire:
Enregistrer un commentaire